Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ars Pharmaceuticals Inc (SPRY)

Ars Pharmaceuticals Inc (SPRY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 927,204
  • Shares Outstanding, K 98,849
  • Annual Sales, $ 89,150 K
  • Annual Income, $ 8,000 K
  • EBIT $ -91 M
  • EBITDA $ -98 M
  • 60-Month Beta 0.79
  • Price/Sales 6.85
  • Price/Cash Flow 1,045.07
  • Price/Book 5.92

Options Overview Details

View History
  • Implied Volatility 162.68% (+47.85%)
  • Historical Volatility 81.36%
  • IV Percentile 97%
  • IV Rank 62.70%
  • IV High 230.00% on 02/09/26
  • IV Low 49.51% on 07/11/25
  • Expected Move (DTE 1) 0.81 (8.54%)
  • Put/Call Vol Ratio 0.19
  • Today's Volume 354
  • Volume Avg (30-Day) 306
  • Put/Call OI Ratio 0.69
  • Today's Open Interest 12,972
  • Open Int (30-Day) 12,585
  • Expected Range 8.64 to 10.26

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.42
  • Number of Estimates 5
  • High Estimate -0.25
  • Low Estimate -0.48
  • Prior Year 0.52
  • Growth Rate Est. (year over year) -180.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.61 +9.76%
on 02/13/26
10.88 -13.14%
on 01/23/26
-1.18 (-11.10%)
since 01/16/26
3-Month
6.66 +41.89%
on 11/21/25
13.15 -28.14%
on 01/12/26
+2.36 (+33.38%)
since 11/18/25
52-Week
6.66 +41.89%
on 11/21/25
18.90 -50.00%
on 06/27/25
-2.32 (-19.71%)
since 02/18/25

Most Recent Stories

More News
ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting

-Five poster presentations highlight clinical advancement of  neffy , real-world usability and advantages of needle-free epinephrine delivery -Longer shelf life of nasal epinephrine compared...

SPRY : 9.45 (+0.75%)
EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to <30 kg

EURneffy 1 mg will be the first and only needle-free adrenaline available to younger children in the European Union ARS Pharma’s partner, ALK-Abelló A/S, who owns the rights to market  EURneffy...

SPRY : 9.45 (+0.75%)
California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use

California joins 23 other states eligible to receive free neffy ® (epinephrine nasal spray) at schools SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY),...

SPRY : 9.45 (+0.75%)
neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis)

neffy is the first epinephrine product approved for use out of a hospital setting in China for adults and children ( > 30 kg) living with severe allergic reactions Pediatrix Therapeutics ,...

SPRY : 9.45 (+0.75%)
ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference

SAN DIEGO, Nov. 26, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves...

SPRY : 9.45 (+0.75%)
ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)

$32.5 million in revenue, including $31.3 million in  neffy U.S. net product revenue in third quarter of 2025 Continued U.S. product growth driven by direct-to-consumer (DTC) investments and...

SPRY : 9.45 (+0.75%)
ARS Pharma Launches Get neffy® on Us for Patients with Severe Allergic Reactions to Improve Access to neffy (epinephrine nasal spray)

Offers no-hassle, free  virtual visit with healthcare provider for patients to receive neffy for $0 co-pay if eligible with commercial insurance Program is available to eligible patients...

SPRY : 9.45 (+0.75%)
UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

ARS Pharma to showcase a late-breaking oral presentation and six poster presentations highlighting real world impact of  neffy ® (epinephrine nasal spray) Oral presentation to report results...

SPRY : 9.45 (+0.75%)
ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results

SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients...

SPRY : 9.45 (+0.75%)
ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

ARS Pharma to showcase a late-breaking oral presentation and six poster presentations highlighting real world impact of  neffy ® (epinephrine nasal spray) Oral presentation reports about 9 out...

SPRY : 9.45 (+0.75%)

Business Summary

ARS Pharmaceuticals Inc. is dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions which could lead to anaphylaxis. The company is developing neffy(TM) an intranasal epinephrine product in clinical development for patients and their caregivers...

See More

Key Turning Points

3rd Resistance Point 9.78
2nd Resistance Point 9.66
1st Resistance Point 9.55
Last Price 9.45
1st Support Level 9.32
2nd Support Level 9.20
3rd Support Level 9.09

See More

52-Week High 18.90
Fibonacci 61.8% 14.22
Fibonacci 50% 12.78
Fibonacci 38.2% 11.34
Last Price 9.45
52-Week Low 6.66

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar